CURRICULUM VITAE

NAME:	**Per Fischer**	**DATE OF BRITH:**	**4th July 1965**
	Vedbendvej 28		
	DK-2900 Hellerup	**PHONE:**	**+45 20 25 20 38**
	Denmark	**EMAIL:**	**pbf@fischer-bioconsult.dk**

EXECUTIVE SUMMARY:

Entrepreneurial leadership type, with 15 years of experience from business development, financing and product development within the biotech and pharma industry. I have a doctorate in cell biology/immunology from University of Oxford. Since my graduation I have worked with product development and business development in larger pharmaceutical companies as well as been involved in establishing and running several biotech companies. I have worked with many different types of products within many different disease areas, but by primary focus has been protein-based and other more complex therapeutics within the areas of vaccines/immunology, haemostasis, oncology and supportive care in cancer.

For several years I have been running by own consultancy company, focusing on project evaluations, business-case building, financing and business development. Translation of complex science into business, development plans and assessment of market opportunities and sizes have played a major part of these activities along with contact to Venture Capital firms and potential Big Pharma Partners.

EDUCATION:

YEAR:	DEGREE:	INSTITUTION:
1996	**Doctor of Philosophy (D.Phil.)** **Virology and biochemistry.**	**Oxford University, UK**
1992	**Master of Science (Cand. Scient.)** **Experimental cellular biology, Immunology.**	**Odense University, DK**

EMPLOYMENT:

YEAR	EMPLOYED WITH	EMPLOYED AS	RESPONSIBILITIES
2008-	**Fischer BioConsult ApS**	**CEO**	*Business Development consultancy: part time CEO, MinervaX ApS (vaccines) ; SVP Business Development, Meabco A/S (oncology); COO Humagene Inc (haemostasis), CEO Helion Holding ApS, Chairman Helion Biotech ApS (immunology), and BD consultant (business strategy, business plans, financing, and partnering) for a number of different clients hereunder: Ascendis Pharma, Orphazyme, CMC Contrast, Cytoguide, InVacc, COBIS, Bridge BioResearch and various Technology Transfer Offices)*
2007-2008	**Novo Nordisk A/S**	**Sourcing Director**	*Soucring and evaluation of new product opportunities. Sourcing Strategy and Business Plan input*
2005-2007	**Novo Nordisk A/S**	**Licensing Director**	*Performing in-licensing and out-licensing of early – late stage development projects. Performing scouting, negotiations, preparing business cases and orchestrating due diligence processes. Presentations to executive management*
2003-2005	**Fischer BioConsult ApS**	**CEO**	*Working as independent consultant within the biotech arena, dealing with project evaluation, business case building, setting up companies, market analysis, product development, and partnering*

2000-2003	**NatImmune A/S**	**President & CEO**	*Setting up the company from scratch raising 23 mUSD and growing to 35 employees in 2 years. Primary work experience include business development, intellectual property licensing (in-licening from academic institutions and partnering discussions), financing & private placements and legal documents (company documents and contracts). Also great experience with development of biological pharmaceuticals, science, manufacturing, regulatory affairs, clinical development, and market assessments. Served as joint CFO, CEO and head of preclinical and clinical development for large periods of the employment*
1998-2000	**Bavarian Nordic Research Institute A/S**	**Manager Preclinical Development**	*Responsible for preclinical development of vaccinia virus vectors for vaccine purposes: production/purification process development; contract manufacture; contract biosafety testing; lot release/QC testing; contract toxicology & biodistribution; regulatory affairs; and Chemistry, Manaufacture and Control sections of IND submissions. Managerial and financial experience as Head of the Preclinical Vector Development Group as well as project manager for academic and clinical collaborations. Experience with Good Laboratory Practice and Good Documentation Practices implementation as project manager*
1996-1998	**Novo Nordisk A/S**	**Virologist, Biologics Development**	*Development of protein therapeutics to European and FDA standards: biosafety testing, virological validation*
1993-1996	**University of Oxford**	**Research Fellow, The Glycobiology Institute**	*Studying the mechanism of action of an HIV drug undergoing clinical development by Searle*
1992-1993	**St. Mary's Hospital Medical School, London**	**Research Fellow, Dept. G.U. Medicine**	*Studying the role of Mannan-binding lectin in the innate immune defence against HIV*

PUBLICATIONS:

1) **P.B. Fischer**, S. Thiel, S.B. Laursen, K.B. Reid, J.C. Jensenius. Rabbit anti-C1q stalk antibodies cross-react with conglutinin, but not with Mannan-Binding Protein or Surfactant Protein A. *Complement and Inflamation, 8:150, 1991.*
2) **P.B. Fischer.** The role of mammalian lectins in the humoral immune defence against viruses. *M.Sc. thesis, Odense University, 1992.*
3) J. Haurum, S. Thiel, I. Jones, **P.B. Fischer**, J.C. Jensenius. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. *AIDS 7:1307-1313, 1993.*
4) **P.B. Fischer**, S. Ellerman, S. Thiel, S. Mogensen, J.C. Jensenius. Mannan-Binding Protein and Bovine Conglutinin mediates infection-enhancement in mice infected with Herpes Simplex Virus, type II. *Scand.J.Immunol 39:439-446, 1994.*
5) R. Malhotra, M.R. Wormald, P.M. Rudd, **P.B. Fischer**, R.A. Dwek, R.B. Sim. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via mannose-binding protein. *Nature Medicine 1:237:243, 1995.*
6) **P.B. Fischer.** Studies on the mechanism of action of the glycosylation inhibitor N-butyldeoxynojirimycin as an inhibitor of HIV replication. *Glycoconjugate Journal 12:574, 1995.*
7) **P.B. Fischer**, G. Karlson, M. Collin, W. James, R.A. Dwek, F. Platt. The a-glucosidase inhibitor N-butyldeoxynojirimycin inhibits HIV entry at the level of post CD4 binding. *J. Virol. 69:5791-5797, 1995.*
8) **P.B. Fischer**, G.B. Karlsson, M. Collin, W. James, R.A. Dwek, F. Platt. N-butyldeoxynojirimycin-mediated inhibition of HIV entry correlates with changes in antibody recognition of the V1/V2 region of gp120. *J.Virol. 70:7143-7152, 1996*.
9) **P.B. Fischer**, G.B. Karlsson, R.A. Dwek, F.M. Platt. N-butyldeoxynojirimycin-mediated inhibition of HIV entry correlates with impaired gp120 shedding and gp41 exposure. *J.Virol. 70:7153-7160, 1996.*
10) **P.B. Fischer**. Studies on the mechanism of action of N-butyldeoxynojirimycin as an inhibitor of HIV replication. *D.Phil. thesis, University of Oxford., 1996.*
11) S.K. Moestrup, H. Birn, **P.B. Fischer**, C.M. Petersen, P. Verroust, R.B. Sim, E.I. Christensen, E. Nexø. Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis. *PNAS, 93:8612-8617, 1996*.
12) U. Holmskov, **P.B. Fischer**, P. Højrup. Affinity and kinetic analysis of the bovine plasma C-type lectin collectin-43 (CL-43) interactin with mannan FEBS lett. 393:314-316, 1996.
13) McBride MO, **Fischer PB**, Sumiya M, McClure MO, Turner MW, Skinner CJ, Weber JN, Summerfield JA. Mannose-binding protein in HIV-seropositive patients does not contribute to disease progression or bacterial infections. Int J STD AIDS 9:683-8, 1998.